PDCD1 and cancer: Fourth, there was a possibility that we could not accurately assess the impact of muscle quality on the OS of patients because it did not directly influence the therapeutic effects of PD‐1/PD‐L1 inhibitors in patients with various statuses with regard to PS, treatment line, driver oncogene, and presence of cancer cachexia.